← Leaderboards
Tanya E. Froehlich
Cincinnati Childrens Hosp Med Ctr
$6,634,365
Attributed
$9,486,060
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,486,060 · 4
By mechanism
R33$4,182,561 · 1
R01$2,918,143 · 1
R61$1,520,829 · 1
K23$864,527 · 1
Top collaborators
- Anna J. Esbensen8 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Joshua Waxman$11,647,448
- Pirooz Eghtesady$2,834,838
- Eileen Catherine King$22,091,258
- Anna J. Esbensen$11,515,885
- Dao Pan$6,892,530
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisImpairmentPharmaceutical PreparationsAttention Deficit Hyperactivity DisorderDoseSymptomsGuidelinesBehavioralChildResponseComorbidityAcademic AchievementRandomizedAreaPlacebosEnrollmentTreatment StrategyAttenuatedCognitiveBehaviorDouble-Blind MethodFunctional DisabilityImpulsivityInattention
Grant awards (19)
Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome$1,080,279
R33 · FY2024 · HD
Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome$379,219
R33 · FY2024 · HD
Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome$1,067,660
R33 · FY2023 · HD
Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome$549,339
R33 · FY2023 · HD
Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome$1,106,064
R33 · FY2022 · HD
Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome$164,639
R61 · FY2021 · HD
Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome$675,867
R61 · FY2020 · HD
Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome$680,323
R61 · FY2019 · HD
Neurobehavioral Effects of Abrupt Methyphenidate Discontinuation$489,932
R01 · FY2019 · MH · contact PI
Neurobehavioral Effects of Abrupt Methyphenidate Discontinuation$552,449
R01 · FY2018 · MH · contact PI
R01 Diversity Supplement$196,204
R01 · FY2018 · MH · contact PI
Neurobehavioral Effects of Abrupt Methyphenidate Discontinuation$541,634
R01 · FY2017 · MH · contact PI
Neurobehavioral Effects of Abrupt Methyphenidate Discontinuation$541,634
R01 · FY2016 · MH · contact PI
Neurobehavioral Effects of Abrupt Methyphenidate Discontinuation$596,290
R01 · FY2015 · MH · contact PI
Medication Response in Children with Predominantly Inattentive Type ADHD$164,974
K23 · FY2013 · MH · contact PI
Medication Response in Children with Predominantly Inattentive Type ADHD$173,776
K23 · FY2012 · MH · contact PI
Medication Response in Children with Predominantly Inattentive Type ADHD$175,608
K23 · FY2011 · MH · contact PI
Medication Response in Children with Predominantly Inattentive Type ADHD$175,064
K23 · FY2010 · MH · contact PI
Medication Response in Children with Predominantly Inattentive Type ADHD$175,105
K23 · FY2009 · MH · contact PI